Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2004

View Archived Issues

TAK-779, a novel immunosuppressant prolongs graft survival in mice

A novel JAK-3 inhibitor, NC-1153, increases graft survival and induces transplantation tolerance

Caspase -3 and -8 inhibition has therapeutic potential in lung transplantation

Array BioPharma highlights Q3 FY 2004 developments

Pharmacyclics continues to advance multiple clinical development programs with Xcytrin

Rigel's development programs proceeding according to plan

Preclinical safety and efficacy of chimeric yellow fever vaccine in non-human primates

Successful synthesis of radiolabeled ENT-103

New phase II trial for Serostim in HARS

ND-1251 enters phase I for depression

Avigen to focus resources on neurological drug candidates

Sanctura receives FDA approval

Not-approvable letter for Pozen's MT-100

ViroLogic and ACLARA BioSciences to merge

PA-457 completes single-dose phase I trial

Second portion of Entereg NDA submitted

First clinical study of ferumoxytol under NCI clinical trial agreement

Cloretazine enters phase II trial for recurrent glioma

NIAID supports phase I trial of Vical's DNA-based anthrax vaccine

Gamunex shown to be safe and efficacious in prospective ITP study

Low-dose RWJ-58643 inhibits the effects of allergen challenge in patients with allergic rhinitis

CDP-870 shows potential in the treatment of asthma

SB-733210, a novel dual NK2/NK3 receptor antagonist with broncholytic and antitussive activity

Sales approval for cefditoren pivoxil in Spain

Janssen researchers describe two series of delta opioid receptor modulators

cPLA2alpha is a novel therapeutic target for asthma therapy

Aventis claims hormone-sensitive lipase inhibitors and their use as antidiabetic agents

Myriad Genetics presents new NK1 antagonists for emesis, pain, etc.

Dual D2/5-HT1A ligands with potential in schizophrenia therapy

Novel macrocyclic lactam with antimicrobial and antitumor activity

Merck KGaA patent covers new factor Xa and factor VIIa inhibitors

New COX-2 inhibitors prepared and tested by Korean team

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.